Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
 & Lead Plaintiff Deadline: June 4, 2018 - EconoTimes)
NEW YORK, April 20, 2018 -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX) and certain of its officers, on behalf of shareholders who purchased Cancer Genetics securities between March 23, 2017 and April 2, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/cgix.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) consequently, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cgix or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Cancer Genetics you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
